|
Gene: TGFA |
Gene summary for TGFA |
Gene summary. |
Gene information | Species | Human | Gene symbol | TGFA | Gene ID | 7039 |
Gene name | transforming growth factor alpha | |
Gene Alias | TFGA | |
Cytomap | 2p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P01135 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7039 | TGFA | LZE4T | Human | Esophagus | ESCC | 3.42e-06 | 1.76e-01 | 0.0811 |
7039 | TGFA | LZE5T | Human | Esophagus | ESCC | 1.99e-04 | 1.93e-01 | 0.0514 |
7039 | TGFA | LZE24T | Human | Esophagus | ESCC | 5.82e-07 | 3.32e-01 | 0.0596 |
7039 | TGFA | P1T-E | Human | Esophagus | ESCC | 8.51e-05 | 6.07e-01 | 0.0875 |
7039 | TGFA | P2T-E | Human | Esophagus | ESCC | 2.84e-26 | 8.98e-01 | 0.1177 |
7039 | TGFA | P4T-E | Human | Esophagus | ESCC | 4.52e-06 | 3.38e-02 | 0.1323 |
7039 | TGFA | P5T-E | Human | Esophagus | ESCC | 1.04e-11 | 2.26e-01 | 0.1327 |
7039 | TGFA | P8T-E | Human | Esophagus | ESCC | 2.31e-16 | 1.75e-01 | 0.0889 |
7039 | TGFA | P9T-E | Human | Esophagus | ESCC | 2.09e-04 | 7.13e-02 | 0.1131 |
7039 | TGFA | P11T-E | Human | Esophagus | ESCC | 3.02e-07 | 3.69e-01 | 0.1426 |
7039 | TGFA | P12T-E | Human | Esophagus | ESCC | 2.24e-12 | 2.51e-01 | 0.1122 |
7039 | TGFA | P15T-E | Human | Esophagus | ESCC | 2.66e-12 | 2.75e-01 | 0.1149 |
7039 | TGFA | P16T-E | Human | Esophagus | ESCC | 3.46e-46 | 1.22e+00 | 0.1153 |
7039 | TGFA | P20T-E | Human | Esophagus | ESCC | 1.93e-08 | 9.86e-02 | 0.1124 |
7039 | TGFA | P21T-E | Human | Esophagus | ESCC | 3.87e-22 | 6.91e-01 | 0.1617 |
7039 | TGFA | P22T-E | Human | Esophagus | ESCC | 1.33e-07 | -9.72e-02 | 0.1236 |
7039 | TGFA | P23T-E | Human | Esophagus | ESCC | 8.79e-03 | 2.38e-01 | 0.108 |
7039 | TGFA | P26T-E | Human | Esophagus | ESCC | 1.96e-20 | 4.28e-01 | 0.1276 |
7039 | TGFA | P27T-E | Human | Esophagus | ESCC | 8.70e-07 | 3.66e-01 | 0.1055 |
7039 | TGFA | P28T-E | Human | Esophagus | ESCC | 4.50e-17 | 3.81e-01 | 0.1149 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002261218 | Skin | SCCIS | gland morphogenesis | 15/919 | 118/18723 | 6.61e-04 | 9.61e-03 | 15 |
GO:20002732 | Skin | SCCIS | positive regulation of signaling receptor activity | 8/919 | 45/18723 | 1.40e-03 | 1.59e-02 | 8 |
GO:007190018 | Skin | SCCIS | regulation of protein serine/threonine kinase activity | 31/919 | 359/18723 | 1.70e-03 | 1.85e-02 | 31 |
GO:00181085 | Skin | SCCIS | peptidyl-tyrosine phosphorylation | 32/919 | 375/18723 | 1.75e-03 | 1.88e-02 | 32 |
GO:00182125 | Skin | SCCIS | peptidyl-tyrosine modification | 32/919 | 378/18723 | 1.98e-03 | 2.06e-02 | 32 |
GO:00507304 | Skin | SCCIS | regulation of peptidyl-tyrosine phosphorylation | 24/919 | 264/18723 | 2.80e-03 | 2.60e-02 | 24 |
GO:0045741 | Skin | SCCIS | positive regulation of epidermal growth factor-activated receptor activity | 4/919 | 13/18723 | 2.89e-03 | 2.66e-02 | 4 |
GO:003087916 | Skin | SCCIS | mammary gland development | 15/919 | 137/18723 | 3.00e-03 | 2.75e-02 | 15 |
GO:007257613 | Skin | SCCIS | liver morphogenesis | 5/919 | 23/18723 | 4.53e-03 | 3.78e-02 | 5 |
GO:00434056 | Skin | SCCIS | regulation of MAP kinase activity | 17/919 | 177/18723 | 6.37e-03 | 4.86e-02 | 17 |
GO:014001415 | Skin | cSCC | mitotic nuclear division | 149/4864 | 287/18723 | 3.59e-21 | 6.43e-19 | 149 |
GO:000734617 | Skin | cSCC | regulation of mitotic cell cycle | 192/4864 | 457/18723 | 3.47e-14 | 2.31e-12 | 192 |
GO:00482854 | Skin | cSCC | organelle fission | 197/4864 | 488/18723 | 1.51e-12 | 8.36e-11 | 197 |
GO:00002803 | Skin | cSCC | nuclear division | 178/4864 | 439/18723 | 1.17e-11 | 5.93e-10 | 178 |
GO:004873227 | Skin | cSCC | gland development | 167/4864 | 436/18723 | 7.64e-09 | 2.44e-07 | 167 |
GO:000188925 | Skin | cSCC | liver development | 69/4864 | 147/18723 | 3.33e-08 | 8.87e-07 | 69 |
GO:006100825 | Skin | cSCC | hepaticobiliary system development | 70/4864 | 150/18723 | 3.56e-08 | 9.33e-07 | 70 |
GO:00070884 | Skin | cSCC | regulation of mitotic nuclear division | 55/4864 | 110/18723 | 5.62e-08 | 1.44e-06 | 55 |
GO:00517832 | Skin | cSCC | regulation of nuclear division | 64/4864 | 139/18723 | 2.49e-07 | 5.25e-06 | 64 |
GO:004578717 | Skin | cSCC | positive regulation of cell cycle | 120/4864 | 313/18723 | 8.95e-07 | 1.64e-05 | 120 |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0521216 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0521118 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0521417 | Esophagus | ESCC | Glioma | 52/4205 | 75/8465 | 4.20e-04 | 1.45e-03 | 7.43e-04 | 52 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa052237 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa05210110 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0521217 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa0521517 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0521119 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0152115 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0521418 | Esophagus | ESCC | Glioma | 52/4205 | 75/8465 | 4.20e-04 | 1.45e-03 | 7.43e-04 | 52 |
hsa0401219 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
TGFA | EGFR | TGFA_EGFR | EGF | CRC | AD |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | AD |
TGFA | EGFR | TGFA_EGFR | EGF | CRC | ADJ |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | ADJ |
TGFA | EGFR | TGFA_EGFR | EGF | CRC | Healthy |
TGFA | EGFR | TGFA_EGFR | EGF | CRC | MSI-H |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | MSI-H |
TGFA | EGFR | TGFA_EGFR | EGF | CRC | SER |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | SER |
TGFA | EGFR | TGFA_EGFR | EGF | Esophagus | ESCC |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | Esophagus | ESCC |
TGFA | EGFR | TGFA_EGFR | EGF | HNSCC | ADJ |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | HNSCC | ADJ |
TGFA | EGFR | TGFA_EGFR | EGF | HNSCC | OSCC |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | HNSCC | OSCC |
TGFA | EGFR | TGFA_EGFR | EGF | HNSCC | Precancer |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | HNSCC | Precancer |
TGFA | EGFR | TGFA_EGFR | EGF | Liver | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TGFA | SNV | Missense_Mutation | c.91N>G | p.Asn31Asp | p.N31D | protein_coding | deleterious(0.05) | probably_damaging(0.987) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
TGFA | insertion | Frame_Shift_Ins | novel | c.92_93insAGTCTTGAAATCTCTTCTCTTAAAATGTCATGCTG | p.Asn31LysfsTer18 | p.N31Kfs*18 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |||
TGFA | insertion | Frame_Shift_Ins | novel | c.93_94insTGCTTTTTAAGCTCAAATGTTGGGGCTGTGCATT | p.Ser32CysfsTer12 | p.S32Cfs*12 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |||
TGFA | SNV | Missense_Mutation | novel | c.163N>A | p.Asp55Asn | p.D55N | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
TGFA | SNV | Missense_Mutation | novel | c.353N>T | p.Ala118Val | p.A118V | protein_coding | tolerated(1) | benign(0.005) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TGFA | SNV | Missense_Mutation | rs372158742 | c.419N>A | p.Arg140Gln | p.R140Q | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TGFA | SNV | Missense_Mutation | novel | c.436N>T | p.His146Tyr | p.H146Y | protein_coding | tolerated(0.1) | possibly_damaging(0.794) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TGFA | SNV | Missense_Mutation | c.101C>T | p.Ser34Phe | p.S34F | protein_coding | tolerated(0.48) | probably_damaging(0.961) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | ||
TGFA | SNV | Missense_Mutation | novel | c.437N>G | p.His146Arg | p.H146R | protein_coding | tolerated(0.13) | possibly_damaging(0.494) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
TGFA | SNV | Missense_Mutation | rs782074408 | c.74C>T | p.Ala25Val | p.A25V | protein_coding | tolerated(1) | benign(0) | TCGA-18-4083-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7039 | TGFA | CELL SURFACE, GROWTH FACTOR, DRUGGABLE GENOME | panitumumab | PANITUMUMAB | ||
7039 | TGFA | CELL SURFACE, GROWTH FACTOR, DRUGGABLE GENOME | LY3016859 | |||
7039 | TGFA | CELL SURFACE, GROWTH FACTOR, DRUGGABLE GENOME | cetuximab | CETUXIMAB |
Page: 1 |